# Helsinn Healthcare SA clinical trials: 32

ClinicalTrials.gov lists 32 trials with Helsinn Healthcare SA as lead sponsor, 1 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Helsinn Healthcare SA: 32 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/helsinn-healthcare-sa

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 1, 2025 | NCT06904235 | Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer... | Helsinn Healthcare SA | Phase 2 | Recruiting | Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06904235) |
| February 21, 2025 | NCT06840769 | A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers | Helsinn Healthcare SA | Phase 1 | Terminated | Healthy Volunteers | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06840769) |
| February 3, 2022 | NCT05222165 | Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3... | Helsinn Healthcare SA | Phase 1/2 | Withdrawn | Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05222165) |
| March 26, 2021 | NCT04817189 | Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) | Helsinn Healthcare SA | Phase 4 | Completed | Chemotherapy-induced Nausea and Vomiting | 414 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04817189) |
| November 15, 2018 | NCT03743064 | A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult... | Helsinn Healthcare SA | Phase 3 | Completed | Cachexia; Cancer, Non Small Cell Lung Cancer | 318 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03743064) |
| November 15, 2018 | NCT03743051 | A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult... | Helsinn Healthcare SA | Phase 3 | Completed | Cachexia; Cancer, Non Small Cell Lung Cancer | 318 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03743051) |
| July 26, 2018 | NCT03601962 | Effects of Aqualief® in Patients With Xerostomia as Consequence of Radiotherapy for Head and Neck Cancer | Helsinn Healthcare SA | Not applicable | Terminated | Xerostomia, Asialia, Hyposalivation, Mouth Dryness | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03601962) |
| April 12, 2018 | NCT03495934 | A Study In Healthy Male Volunteers Designed To Investigate How A Radiolabelled Medicine Is Broken Down And Removed From The Body | Helsinn Healthcare SA | Phase 1 | Completed | Healthy Subjects | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03495934) |
| January 19, 2018 | NCT03403712 | A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral... | Helsinn Healthcare SA | Phase 3 | Completed | Chemotherapy-induced Nausea and Vomiting | 404 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03403712) |
| August 21, 2017 | NCT03255980 | Monocenter, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Xonrid® | Helsinn Healthcare SA | Not applicable | Completed | Radiodermatitis, Quality of Life | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03255980) |
| July 2, 2017 | NCT03204279 | PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting | Helsinn Healthcare SA | Phase 2 | Completed | Chemotherapy-induced Nausea and Vomiting (CINV) | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03204279) |
| May 12, 2017 | NCT03151408 | An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia | Helsinn Healthcare SA | Phase 3 | Terminated | Acute Myeloid Leukemia | 406 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03151408) |
| May 12, 2017 | NCT03151304 | A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes | Helsinn Healthcare SA | Phase 2 | Terminated | Myelodysplastic Syndromes | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03151304) |
| August 30, 2016 | NCT02883790 | Effects of Somnage® in the Management on Sleep and Mood in Cancer Patients | Helsinn Healthcare SA | Not applicable | Terminated | Breast Cancer, Lung Cancer, Colon Cancer | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02883790) |
| August 25, 2016 | NCT02877966 | Evaluation of the Effects of a Mixture of Amino Acids (Amixea) on Lean Body Mass and Muscle Strengh of Patients With Unresectable Advanced... | Helsinn Healthcare SA | Not applicable | Withdrawn | Cancer Patients With Cachexia | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02877966) |
| September 22, 2015 | NCT02557035 | An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and... | Helsinn Healthcare SA | Phase 3 | Completed | Chemotherapy-Induced Nausea and Vomiting | 441 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02557035) |
| August 6, 2015 | NCT02517021 | A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting | Helsinn Healthcare SA | Phase 3 | Completed | Chemotherapy-Induced Nausea and Vomiting | 405 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02517021) |
| March 9, 2015 | NCT02383810 | Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide in the Prevention... | Helsinn Healthcare SA | Phase 2 | Completed | Drug and/or Toxin-induced Diarrhea | 498 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02383810) |
| April 21, 2014 | NCT02118909 | Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking Subjects | Helsinn Healthcare SA | Phase 1 | Completed | Healthy Volunteers, Non-smokers | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02118909) |
| February 10, 2014 | NCT02058784 | Study to Evaluate the Food Effect of Single-dose Bioavailability of Pracinostat in Healthy Adult Subjects | Helsinn Healthcare SA | Early phase 1 | Completed | Healthy Volunteers, Moderate to Heavy Smokers, Non-smokers | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02058784) |
| November 25, 2013 | NCT01993641 | Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA | Helsinn Healthcare SA | Phase 2 | Completed | Myelodysplastic Syndrome, MDS | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01993641) |
| July 31, 2013 | NCT01912274 | Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | Helsinn Healthcare SA | Phase 2 | Completed | Acute Myeloid Leukemia | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01912274) |
| June 26, 2013 | NCT01887314 | Efficacy Study of Ginger (Zingiber Officinale) Extract "Ginpax" to Manage Nausea in Cancer Patients Receiving High Emetogenic Treatments... | Helsinn Healthcare SA | Not applicable | Completed | Cancer, Nausea, Vomiting | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01887314) |
| June 10, 2013 | NCT01873703 | Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome | Helsinn Healthcare SA | Phase 2 | Completed | Myelodysplastic Syndrome | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01873703) |
| March 5, 2012 | NCT01543451 | Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea | Helsinn Healthcare SA | Phase 2 | Completed | Diarrhea | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01543451) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 3 |
| Phase 1/2 | 1 |
| Phase 2 | 8 |
| Phase 3 | 13 |
| Phase 4 | 1 |
| Not applicable | 5 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 23 |
| Terminated | 6 |
| Withdrawn | 2 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Vomiting | 12 |
| Myelodysplastic Syndromes | 3 |
| Neoplasms | 3 |
| Leukemia, Myeloid, Acute | 2 |
| Cachexia | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Postoperative Nausea and Vomiting | 2 |
| Nausea | 2 |
| Radiodermatitis | 1 |
| Biliary Tract Neoplasms | 1 |
| Cholangiocarcinoma | 1 |
| Gallbladder Neoplasms | 1 |
| Bile Duct Neoplasms | 1 |
| Xerostomia | 1 |
| Diarrhea | 1 |
| Central Nervous System Neoplasms | 1 |
| Breast Neoplasms | 1 |
| Lung Neoplasms | 1 |
| Colonic Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Computer wholesalers in the United States](https://specstream.ai/data/businesses/computer-wholesalers/united-states)
- [Duplication companies in the United States](https://specstream.ai/data/businesses/duplication-companies/united-states)
- [Ferry boat companies in the United States](https://specstream.ai/data/businesses/ferry-boat-companies/united-states)
- [Haitian restaurants in the United States](https://specstream.ai/data/businesses/haitian-restaurants/united-states)
- [Insurance agencies in the United States](https://specstream.ai/data/businesses/insurance-agencies/united-states)
- [Machine shops in the United States](https://specstream.ai/data/businesses/machine-shops/united-states)
